MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
688180.SS stock logo

688180.SS

Shanghai Junshi Biosciences Co., Ltd.

$39.8
-0.92
 (-2.26%)
Exchange:  SHH
Market Cap:  40.031B
Shares Outstanding:  890.012M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Cong Li
Full Time Employees:  2578
Address: 
Building 7
Shanghai
200126
CN
Website:  https://www.junshipharma.com
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People’s Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences’ anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People’s Republic of China.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,502,549.9141,948,317.3152,498,420.333
Gross Profit868,156.8971,424,779.8241,967,444.081
EBITDA-2,190,363.754-1,046,556.501-762,055.820
Operating Income-2,457,442.353-1,338,824.837-999,463.383
Net Income-2,283,431.856-1,280,926.434-875,174.329

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets11,342,866.87110,800,08812,382,326.895
Total Liabilities4,022,256.3864,849,8316,158,561.766
Total Stockholders Equity7,151,224.1865,878,5516,030,434.432
Total Debt1,788,5672,930,8884,141,845.710
Cash and Cash Equivalents3,788,193.3762,486,6792,614,544.505

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-2,004,982.103-1,442,841-478,144.454
Capital Expenditure-832,574.528-690,988-768,298.596
Free Cash Flow-2,847,539-2,133,829-1,246,443.050
Net Income-2,489,887-1,359,028-875,174.332
Net Change in Cash-2,218,794-1,291,463113,362.220

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2028Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)4,674,405.451Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)4,961,120.758Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)4,762,000Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-2,909,668.240Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-2,741,511.393Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-2,792,885.083Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)248,517.548Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)268,447.596Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)254,608.122Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)3,312,517.428Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)3,515,698.231Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)3,374,591.306Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0.250Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0.270Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.250Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)2Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)3Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
18.13
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-53.61
?Enterprise Value
 (TTM)
: 
46.829B  ?EV/FCF
 (TTM)
: 
-37.06
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
-0.05
?ROE
 (TTM)
: 
-0.14  ?ROIC
 (TTM)
: 
-0.09
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.69
?P/B
 (TTM)
: 
7.78  ?Current Ratio
 (TTM)
: 
1.6

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate SS Intrinsic Value

Common questions about 688180.SS valuation

Is Shanghai Junshi Biosciences Co., Ltd. (688180.SS) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Shanghai Junshi Biosciences Co., Ltd. (688180.SS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is 688180.SS a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether 688180.SS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is 688180.SS’s P/E ratio?

You can see 688180.SS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for 688180.SS?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is 688180.SS a good long-term investment?

Whether 688180.SS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

688180.SS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-2.26
MARKETSnap

Trading Metrics:

Open: 40.31   Previous Close: 40.72
Day Low: 39.24   Day High: 40.73
Year Low: 28.24   Year High: 51.4
Price Avg 50: 35.51   Price Avg 200: 38.39
Volume: 18.865M   Average Volume: 17.47M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
Could not create stock discussion for SS

Relevant news

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read